Replicated international studies have underscored the human and societal costs associated
with major depressive disorder. Despite the proven efficacy of monoamine-based …

Treatment of major depressive disorder (MDD) including treatment-resistant depression
(TRD) remains a major unmet need. Although there are several classes of dissimilar …

Background: The introduction of esketamine into the field of psychiatry comes on the heels
of excitement from studies on racemic ketamine. While the intranasal route has been the …

Treatment-resistant depression (TRD) is a term used to describe a particular type of major
depressive disorder (MDD). There is no consensus about what defines TRD, with various …

Objective Evidence-based treatment options for late-life treatment-resistant depression
(TRD) are limited. Ketamine is a promising treatment for TRD; however, there is a paucity of …

Objective The aim of this study was to estimate the cost-effectiveness of esketamine nasal
spray relative to intravenous ketamine for patients with treatment-resistant depression (TRD) …

BackgroundIntravenous infusion of ketamine can produce rapid and large symptom
reduction in patients with treatment-resistant depression (TRD) but presents major obstacles …

About one-third of patients with depression do not achieve adequate response to current
treatment options. Although intravenous and intranasal administrations of (es) ketamine …

Background The extraordinarily high prevalence of treatment-resistant depression (TRD),
coupled with its high economic burden to both healthcare systems and society, underscore …

Background Electroconvulsive therapy (ECT) has long been used for treating individuals
with treatment-resistant depression (TRD). Esketamine has recently emerged as a new …